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Abstract 
Title 
PATIENTS TREATED WITH RADICAL COURSE OF RADIATION THERAPY 
FOR CARCINOMA OF THE LARYNX AT CHARLOTTE MAXEKE 
JOHANNESBURG ACADEMIC HOSPITAL 
 
Background 
Larynx preservation is the standard recommended treatment approach for cancer of the 
larynx. We looked at results of patient treated with larynx preserving approach at our 
institution.    
Objectives 
The study objectives included describing the demographics of the population in the study and 
comparing characteristics and outcomes for patients in the different treatment groups. We 
also assessed waiting time for treatment, treatment completion rates and overall treatment 
time for all the patients in the study group. Outcomes of patients at last follow up and 
survival for different stages of disease were described.  
Materials and Methods 
A retrospective study of patients with cancer of the larynx treated at Charlotte Maxeke 
Academic Hospital department of radiation oncology between the year 2007 and 2009. All 
patients who received radiotherapy including palliative and radical cases were assessed. 
Outcomes were measured from end of treatment to 1 year and 2 years follow up for survival. 
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Results   
We identified 106 eligible patients. The mean age was 58.6 years (standard deviation of 
10.051).Two thirds (67%) of the patients presented with stage IVa disease, 14% had stage 
IVb, 13% had stage III, and very few patients had stage I and II disease 4% and 2% 
respectively. One third of patients were treated with radical chemotherapy plus radiotherapy 
and majority of them received only 1 cycle of chemotherapy. The other 26 % of patients 
treated with radical intent received radiotherapy alone. A significant number of our patients 
(42 %) were treated with palliative intent of which 13 % were patients who had disease 
progression while awaiting treatment. The majority of patients (53%) had an improvement in 
symptoms while (5.7%) had died and (17%) were lost to follow-up. 
Conclusion 
Waiting time prior to radiotherapy is a major problem in our institution as our overall mean 
waiting time was 98.5 days. Patients who had disease progression as defined by change in the 
treatment intent from radical to palliative treatment (13%) had a mean waiting time of 187.9 
days which was almost double our overall mean waiting time and significantly worse than 
that recommended by standard of care. Although this waiting time was not statistically 
significant when compared with other patients treated with radical intent, it is a concern for 
the department to have such long waiting time prior to therapy and is probably a reflection of 
inadequate statistical power. 
 Of the radical cases those treated with chemotherapy and radiotherapy very few (2.9%) 
completed 3 cycles of chemotherapy therefore we had low treatment completion rates. Some 
patients did not receive their 2
nd
 or 3
rd
 cycle of chemotherapy due to low creatinine clearance 
other patients reasons for not completing chemotherapy was not documentation in their 
medical records. Although concurrent chemotherapy plus radiotherapy is the standard of care 
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for larynx preservation, most of our patients received suboptimal treatment to the 
recommended schedule and a significant number of our patients were treated with palliative 
intent. 
Chemotherapy was not administered in some patients because of low CD4 count value. 
Unfortunately this was not recorded systematically and HIV status was not an entry or 
exclusion factor so no comparisons could be made. The chemotherapy schedule was not 
given to many patients at the recommended schedule of 3 cycles so we were not able to 
compare this with the literature. 
Resources constraints with regards to diagnostic and radiological facilities resulted in us not 
having measurable tumour volume increase to evaluate disease progression during waiting 
time and to evaluate response to treatment at follow-up. 
We have identified that patients are receiving inadequate treatment at the Department of 
Radiation Oncology with waiting times in excess of that recommended in the literature. 
Several reasons have been tentatively identified. 
 Additional research in a form of prospective study is required in our department to assess if 
we could improve the number of patients treated with radical intent by giving induction 
chemotherapy during the waiting time for patients with advanced stage III & IV disease who 
have a good performance status. Protocols in our department need to be reviewed for patients 
with early disease to be treated with shorter regimen and a higher dose fractionation schedule 
of 2.25Gy as this will also reduce our overall treatment time and waiting time for treatment 
while improving local control. 
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1. Introduction 
This research report will briefly discuss the anatomy and pathology of the larynx and look at 
the risk factors for cancer of the larynx, staging and treatment with radiation therapy. It will 
detail the results of patients treated for cancer of the larynx at Charlote Maxeke Johannesburg 
Academic Hospital with radiation therapy discussing their treatment tolerability, 
completeness of treatment and outcome. 
1.1.1 Anatomy of the larynx 
The larynx is a very important organ of phonication also known as “Voice box”. It is situated 
between the pharynx above and the trachea below. Apart from phonation, the larynx acts as a 
valve for preventing swallowed food and foreign bodies from entering the lower respiratory 
passage. It is divided into 3 regions i.e. supraglottic region, glottic region and subglottic 
(Figure 1.1.1). 
 
 
 
Figure 1.1.1 Anatomy of the larynx showing supraglottic, glottis and subglottic region. Credit to Miles Kelley art Library. 
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The supraglottic larynx consist of the epiglottis, false vocal cords, the ventricles and 
aryepiglottis folds including the arytenoids. The glottis region includes the true vocal cords 
and the anterior commissure, the subglottis is located below the vocal cords. The glottis is the 
part of the larynx most directly concerned with voice production (Moore KL, 1992). The 
shell of the larynx is formed by the hyoid bone, thyroid cartilage and the cricoid cartilage 
(Figure 1.1.2). 
 
Figure 1.1.2The lateral view of the larynx, hyoid bone above, thyroid cartilage in the middle and cricoids cartilage below 
connecting to trachea. Credit to Netter’s Atlas. 
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The supraglottic region has a rich capillary lymphatic plexus and initially drains to level II 
and then III and IV lymph nodes (Devita, 2008) Figure 1.1.3. There is essentially no capillary 
lymphatic of the glottis (true vocal cord) region. Lymphatic spread from cancer at the glottis 
only occurs if tumour extends to supraglottic or subglottic areas (Perez and Brady, 2008). The 
subglottic area has relatively few capillary lymphatics and spread is primarily to the pre-
tracheal (delphian) nodes and the level IV nodes (Figure 1.1.3).  
 
Figure 1.1.3 Picture showing anatomy of lymph node levels for head and neck. Credit to F. Gaillard.  
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 Level I: Ia = submental, Ib = submandibular nodes. 
Level II: upper deep cervical, extending from skull base to hyoid 
 Level III: mid deep cervical, extending from hyoid to cricoid 
Level IV: lower deep cervical, extending from cricoids to clavicle 
Level V: posterior cervical, bounded by sternomastoid, trapezius and clavicle 
 
1.1.2 Laryngeal Pathology 
The pathological disorders of the larynx include inflammatory e.g. laryngitis, epiglottitis 
commonly caused by infections such as H.Influenza or allergic reactions. Benign laryngeal 
polyps usually develop in singers and are sometimes called ‘singers nodes’. 
 Tumours of the larynx may be benign e.g. papillomas or malignant mostly squamous cell 
carcinoma (Underwood J.C.E, 1996). Squamous cell carcinoma accounts for at least 95% of 
malignant cancers of the larynx and the other 5% of cancers comprise lymphomas, small cell 
carcinomas, soft tissue sarcomas and metastatic disease accounts for 5% of cancers of the 
larynx (Leibel and Phillips, 2010). Verrucous carcinoma is an uncommon but distinct variety 
of squamous cell carcinoma. It is a bulky, exophytic, papillomatous, low–grade squamous 
cell carcinoma (Leibel and Phillips, 2010).     
Carcinomas arising from true vocal cords are usually well differentiated or moderately 
differentiated whereas carcinomas of the supraglottis and subglottis are less differentiated 
(Leibel and Phillips, 2010). Carcinoma in situ (CIS) occurs in vocal cords but is rare in the 
supraglottis.  
 Carcinoma of the larynx represents about 2% of total cancer risk and is the most common 
head and neck cancer. About 51% of cancer of the larynx remains localized, 29% have 
regional spread and 15% have distant metastasis at the time of diagnosis (Perez and Brady, 
2008). Cancer of the larynx is strongly related to cigarette smoking and is more prevalent in 
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males than females (Perez and Brady, 2008).The contribution of smoking and alcohol is 
greater for supraglottic cancer than glottis cancer. Other rare risk factors include exposure to 
asbestos, diesel fumes, rubber and wood dust. People who employ their voices extensively 
also appear to be at higher risk of developing larynx cancer (Leibel and Phillips, 2010). 
1.1.3 Clinical Presentation  
 The most common presenting symptom is hoarseness of voice if cancer affects the glottis 
region (true vocal cord) but it may not be prominent feature if the tumour is in the 
supraglottic or subglottic region unless it becomes quite extensive (Perez and Brady, 2008). 
Other common symptoms are sore throat or a feeling of a ‘lump in the throat’ or earache 
where pain is referred to the ear by the vagus nerve. Late symptoms include dysphagia, 
weight loss, foul breath and airway obstruction and aspiration (Perez and Brady, 2008). 
Initial evaluation of patients with laryngeal cancer includes careful history and physical 
examination as these patients may have other co-morbidities associated with smoking e.g. 
chronic obstructive pulmonary disease (COPD), pulmonary tuberculosis, or other primary 
tumours. 
 
1.1.4 Investigations and Staging 
 The important investigations for diagnosis and staging include flexible fibre optic 
laryngoscopy which complements the laryngeal mirror as the procedure can be performed in 
the office. As the scope is inserted through the nose it is particularly useful in more difficult 
cases (Perez and Brady, 2008).The extent of tumour invasion and mucosal spread can be 
assessed as well as the mobility of the vocal cords for staging as fixed or partially mobile 
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cords are suggestive of a more advanced lesion (Perez and Brady, 2008). Biopsy of the lesion 
can also be taken during the examination. 
 Rigid Direct Laryngoscopy requires anaesthesia but allows better visualization and is the 
most valuable and essential step in the diagnosis and staging of cancer of the larynx (Leibel 
and Phillips, 2010). CT scan with contrast enhancement and / or MRI are useful in providing 
information about extra-laryngeal spread of disease, cartilage invasion and nodal metastases. 
The relative usefulness of CT scan versus MRI remains controversial and in many cases the 
two modalities are complementary (Leibel and Phillips, 2010). These studies are preferably 
performed before biopsy as post biopsy oedema may cause overestimation of tumour extent. 
 Metastatic work up includes chest X-ray and lab tests( FBC, LFT) to check liver function 
and if  test are abnormal then liver ultrasound scan and bone scan are indicated. Anaemia is 
important to diagnose as it may be a negative prognostic factor for patients with cancer of the 
larynx who receive radiation therapy (Leibel and Phillips, 2010).   
 After investigations are completed the cancer is staged using the American Joint Committee 
on Cancer (AJCC-TNM) staging system (Appendix 1) which describes T1-T4 for the 3 
different regions of the larynx i.e. supraglottis, glottis and subglottis region.  
 Tis= tumor in situ/ carcinoma in situ, T= invasive tumor extent, N= Nodal involvement and 
M= Metastases (see appendix 1 for the T-N-M stage)  
 The AJCC also developed the stage grouping which groups the TNM stage into stage 0 to 
stage IVC shown below. Group stage 1 and 2 are considered early stage carcinoma while 
group stage 3 and 4 are advanced cancer of the larynx. 
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Table 1.1     Group staging for cancer of the larynx 
Stage 0 Tis  N0  M0 
Stage I  T1  N0  M0 
Stage II T2  N0  M0 
Stage III T3  N0  M0 
  T1  N1  M0 
  T2  N1  M0 
  T3  N1  M0 
Stage IVA T4a  N0  M0 
  T4a  N1  M0 
  T1  N2  M0 
  T2  N2  M0 
  T3  N2  M0 
  T4a  N2  M0 
Stage IVB T4b  Any N  M0 
  Any T  N3  M0 
Stage IVC Any T  Any N  M1 
 
AJCC: American Joint Committee on Cancer stage grouping (Hansen EK; Roach M, 2010).   
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1.2 Treatment overview for cancer of the larynx  
The choice of treatment modality depends on tumour stage, performance status, co-morbidity, 
functional outcome, and survival rate. Assessment in a multidisciplinary clinic is essential 
The goal of treatment for laryngeal cancer is to cure with the best functional results and the 
least risk of serious complications. 
1.2.1 Role of Surgery  
a) Stripping or CO2 laser 
Lesions diagnosed as carcinoma in situ may be treated by stripping the vocal cord or excision 
using CO2 laser (Perez and Brady, 2008). It is however difficult to exclude the possibility of 
micro-invasion on the specimen therefore recurrences are frequent. The vocal cord may 
become thickened with repeated stripping and leading to hoarse voice (Perez and Brady, 
2008) 
b) Cordectomy  
Cordectomy is an excision of the vocal cord and may be performed by transoral approach 
usually with a laser or externally by a thyrotomy (Perez and Brady, 2008). Its use is usually 
confined to small lesions of the middle third of the cord, early T1 lesions. After cordectomy a 
pseudo cord is formed and the patient is left with a useful somewhat harsh voice. 
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c) Vertical Partial Laryngectomy ( Hemilaryngectomy)     
One entire vocal cord with as much as a third of the opposite cord and adjacent thyroid 
cartilage is the maximum cord involvement suitable for this surgery in men. Women have 
smaller larynx usually only one vocal cord may be removed without compromising the 
airway (Perez and Brady, 2008).Hemilaryngectomy is contraindicated if tumor extends to the 
epiglottis, false vocal cords or both arytenoids. 
d) Supracricoid Partial Laryngectomy   
Supracricoid partial laryngectomy is used for selected T2 & T3 glottic carcinomas and entails 
removal of both the true and false vocal cords and the entire thyroid cartilage. The cricoid is 
sutured to the epiglottis and hyoid (cricohyoidoplexy) (Perez and Brady 2008). 
e) Total Laryngectomy  
Total laryngectomy with or without neck dissection is the operation of choice for advanced 
lesion and as a salvage procedure for radiation therapy failures in lesions that are not suited 
for conservation surgery. The entire larynx is removed and the pharynx is reconstructed. 
1.2.2 Management of early stage I & II cancer of the larynx 
Early stage I & II cancer of the larynx can effectively be treated with surgery or radiation 
therapy. Treatment guidelines emphasize that every effort should be made to avoid 
combining surgery and radiotherapy because functional outcomes may be compromised 
(Leibel and Phillips, 2010). Patients who are considered not reliable enough for close follow 
up may benefit from upfront surgery (Leibel and Phillips, 2010)  
Radiotherapy is the preferred larynx preserving treatment for early stage cancer of the larynx 
with surgery reserved for salvage after radiation failure (Perez and Brady 2008).  Larynx 
 
 
10 
 
preservation is achieved in 78-95% patients treated with radiotherapy for T1 lesion and 71-
88% with T2 lesion (Leibel and Phillips, 2010).  
(Mittal B et al, 1983) retrospectively analysed survival, tumour control, voice preservation 
and complications in patients with early T1/T2 laryngeal cancer treated with radiotherapy. 
Their 5 and 10 year survival rates were 97% and 95%, respectively. The tumour was 
ultimately controlled in 97% of patients and voice was preserved in 93% of their patients. 
(Mendenhall WM et al, 2001) analysed patient related and treatment related parameters that 
may influence the likelihood of cure in patients with T1-T2 laryngeal cancer treated with 
radiotherapy and found that the major treatment related parameter that influenced cure was 
overall treatment time. They found that radiotherapy cured a high percentage of patients with 
T1-T2 cancer of larynx and had a low rate of severe complications. 
In a retrospective study by (Cellai E et al, 2005) where they looked at results of 1087 patients 
with T1N0 cancer of the glottis treated with radical radiotherapy from two Italian radiation 
oncology centres. They found that the 3, 5 and 10 years local control rate was 86%, 84% & 
83% respectively while the overall survival rate was 86%, 77% and 57% respectively.   
(Johansen L.V et al, 1990) analysed primary radiotherapy for T1 squamous cell carcinoma of 
the larynx in 478 patients treated from 1963- 1985. Their 10 year survival for supraglottis and 
glottis tumours were 67% and 94%. They found that the major problems were new primary 
cancers which within 20 years occurred in 34 % of patients for supraglottis and 23% for 
glottis patients. 
(Yamazaki H et al, 2006) also found that shorter overall treatment time showed superior local 
control for patients with T1N0M0 cancer of larynx treated with radiation therapy. In their 
randomised prospective study they compared local control for two fractionation regimens of 
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2Gy and 2.25Gy and the 5 year local control rate was 77% for the 2Gy arm and 92% for the 
2.25Gy arm. No significant differences were found between the two arms in terms of adverse 
reactions. 
 American Society of Clinical Oncology (ASCO) convened an Expert Panel under the 
auspices of the Health Services Committee to develop recommendations regarding the 
appropriate application of larynx-preservation therapies (Pfister D.G et al, 2006). They 
recommend that all patients with T1 or T2 laryngeal cancer, with rare exception, should be 
treated initially with intent to preserve the larynx.  
The incidence of lymph node involvement for T1 lesion is close to zero and for T2 lesion is 
2% (Perez and Brady, 2008) therefore the treatment field is usually a small portal covering 
the primary lesion only, lymph nodes are not included as shown in Figure1.2.1below. 
Commonly used dose fractionation schedules at many institutions for early cancer of the 
larynx T1-T2 lesion is 66Gy/33# (2Gy per fraction) daily (Perez and Brady, 2008). Evidence 
suggests that increasing the dose per fraction may improve the likelihood of local control as 
shown in the study by (Yamazaki H et al, 2006).  
A study of modest size fixed field radiotherapy approach for clinically node-negative 
supraglottic carcinoma of the larynx showed that treating a modest size fixed field to a high 
biologically effective dose is highly effective and enables preservations of larynx with 
acceptable regional control and no loss of survival compared to whole neck radiotherapy 
regimes (Sykes A.J et al, 2000). 
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Figure 1.2.1 Treatment portal for early stage cancer of the larynx. Extent of field indicated by bold red line, field size 
usually 6x6 cm). Digitally reconstructed radiographs (DRR’s) from Charlotte Maxeke Johannesburg Academic Hospital. 
 
1.2.3 Management of advanced stage III & IV cancer of the larynx 
 
In the 1980’s total laryngectomy was the standard treatment for locally advanced stage III & 
IV cancer of the larynx. Postoperative radiation was often needed in these patients if surgical 
margins were positive, tumour extended into soft tissues, subglottic extension > 1cm, 
cartilage invasion, perineural invasion, multiple positive lymph nodes & extracapsular 
invasion (Pfister D.G et al, 2006). Partial laryngectomy and radiation therapy were the 
recommended therapeutic options for selected patients, hoping to avoid total laryngectomy 
(Pfister D.G et al, 2006).   
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Definitive radiation therapy alone was reserved for medically inoperable patients (Perez and 
Brady, 2008).The results of radiation alone proved to be suboptimal when compared with 
radiation therapy given after surgery in the long term follow up study of RTOG 73-03 
(Tupchong L et al, 1991).This phase 3 study of preoperative (50.0Gy) versus postoperative 
radiation therapy (60.0Gy) for supraglotitc larynx and hypopharynx primaries showed 78% of 
loco-regional failure occurring in the first two years when considering only supraglottic 
larynx. Preoperative patients had 31% local failure rate within two years versus 18% of 
postoperative patients. After two years distant metastases and second primaries became 
predominant failure pattern especially in postoperative radiation therapy patients. The study 
showed no advantage in absolute survival for postoperative patients and the rates of severe 
surgical and radiation therapy complications where similar between the two arms (Tupchong 
L et.al, 1991).     
Total laryngectomy in patients with stage III or IV cancer of the larynx currently is reserved 
as salvage therapy for local failures after larynx preserving non surgical treatment approach 
or for patients with extensive cartilage involvement. 
(Webber R S et.al, 2003) looked at the outcome of salvage total laryngectomy (TL) following 
organ preservation therapy. The study evaluated the incidence of morbidity, mortality and 
disease control for patients requiring salvage total laryngectomy following organ preservation 
therapy from 1992 to 2000. It concluded that laryngectomy following organ preservation 
therapy was associated with acceptable morbidity. Peri-operative mortality was low but up to 
one third of patients developed a pharyngocutaneous fistula, locoregional control following 
salvage TL was good more than 74% and survival was not influenced by the initial organ 
preservation treatment. 
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a) Larynx preserving treatment approach for stage III and IV cancer 
In 1991 the landmark Veterans Affairs (VA) laryngeal cancer study first established the role 
of chemotherapy as part of a larynx preserving treatment strategy for advanced laryngeal 
cancer stage III and IV disease (Wolf et al, 1991). This trial provided the best initial evidence 
to support cisplatin based induction chemotherapy as part of a larynx preserving treatment 
approach. They randomised patients with stage 3 or 4 laryngeal cancer to primary surgery 
followed by post operative radiotherapy versus 3 cycles of induction chemotherapy followed 
by radiation therapy if patients showed response to chemotherapy after 2 cycles. Those 
patients who had no response or showed disease progression after chemotherapy were treated 
with surgery (total laryngectomy) instead of radiation therapy. Surgery was also reserved for 
patients who relapsed after radiation as salvage therapy. The chemotherapy and radiotherapy 
arm yielded survival rates comparable to those achieved with primary surgery and two thirds 
of the patients retained their larynx function. 
The EORTC Head and Neck Cancer Cooperative Group in 1996 further supported the 
principles of the VA trial. The prospective study aimed at comparing larynx preserving 
treatment (induction chemotherapy plus definitive radiation therapy in patients who showed 
complete response or surgery in those who did not) with conventional treatment (total 
laryngectomy with radical neck dissection and post-operative radiation) Lefebvre JL et al, 
1996. The study showed a median duration of survival of 25 months in the immediate surgery 
arm and 44 months in the induction chemotherapy arm resulting in the treatments being 
judged to be equivalent. The 3 and 5 years estimate of retention of a functional larynx in 
patients treated in the induction chemotherapy arm was 42% and 35% respectively. In 
conclusion larynx preservation without jeopardising survival is feasible with the use of 
induction chemotherapy followed by radiotherapy (Lefebvre JL et al, 1996). 
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 A randomized trial of induction chemotherapy with cisplatin (P) and 5-fluorouracial (F) with 
or without docetaxel for larynx preservation suggested that docetaxel (T) may add to the 
efficacy of PF(Pointreau Y et.al, 2009).The objective of this trial was to determine whether 
adding T to PF could increase the laryngeal preservation rate. Results showed that in patients 
with advanced larynx and hypopharynx carcinomas, TPF induction chemotherapy was 
superior to the PF regimen in terms of overall response rate. These results suggest that larynx 
preservation could be achieved for a higher proportion of patients (Pointreau Y et.al, 2009). 
The primary objective of combining chemotherapy with radiation therapy (concurrent chemo-
irradiation) was to achieve an improved therapeutic result which could be evaluated as a 
function of enhanced tumour response or reduced normal tissue toxicity (Leibel and Phillips, 
2010).Chemotherapeutic agent e.g. cisplatin act as both radiosensitizers and also provide 
additive cytotoxicity ( Perez and Brady, 2008). Four mechanisms were described by (Steel 
GG et al, 2000) in which combined modality therapy i.e. chemotherapy plus radiation could 
improve therapeutic outcome: 1) spatial cooperation, 2) toxicity independence, 3) protection 
of normal tissue, 4) enhancement of tumour response  
The Radiation Therapy Oncology Group (RTOG) Study 91-11undertaken in collaboration 
with head and neck intergroup and published in 2003 established the use of concurrent 
chemotherapy with radiation as the superior non surgical larynx preserving strategy 
(Forastiere A.A et al, 2003). The study demonstrated that patients with advanced laryngeal 
cancer receiving concurrent cisplatin and radiation had a better larynx preservation rate of 
84% at a median follow up of 3.8 years compared to that afforded either by radiation alone 
(67%) or by induction cisplatin / 5FU followed by radiation (72%) Forastiere AA et al,2003. 
Chemotherapy concurrently with radiation therapy in head and neck cancers showed survival 
benefits in the Meta-Analysis of chemotherapy in head and neck cancer group (MACH-NC) 
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Pignon JP et al, 2007. The study identified that the addition of chemotherapy to loco-regional 
treatment provides a modest overall improvement in survival (4% at 5years) for patients with 
loco-regionally advanced head and neck cancer. There was a (8%) benefit with the use of 
concomitant chemotherapy and radiotherapy with no significant benefit for the use of 
induction or adjuvant chemotherapy (Pignon JP et.al, 2007). 
 In a phase 2 trial of chemo-radiotherapy as the primary therapy for locally advanced head 
and neck cancers, cisplatin, infusional fuorouracil and hydroxyurea were used along with 
radiation therapy twice daily at 1.5 Gy/fraction on days 1-5 (total dose-15 Gy). Five days of 
treatment were followed by 9 days of rest, during which time patients received granulocyte 
colony-stimulating factor. At a median follow-up of 38 months, the 3 year progression-free 
survival was 72%, loco-regional control 92%, systemic control was 83%, and overall survival 
55%. Toxicities included mucositis (grade 3= 45%; 4= 12%), neutropenia (grade 4= 39%), 
and thrombocytopenia grade 4= 53% (RTOG appendix 3). They concluded that intensive 
concomitant chemotherapy plus radiotherapy leads to high loco-regional control and survival 
rates with organ preservation and a reversal of the historical pattern of failure (distant > loco-
regional) Vokes E.E et.al,2000.   
 There has been growing interest in identifying molecular markers to predict disease outcome.  
Cetuximab a monoclonal antibody against EGFR (epidermal growth factor receptor) has been 
used to enhance cytotoxic effect of radiation therapy for head and neck cancers. This drug has 
not been directly compared with cisplatin but may be considered for patients who have co-
morbidities that contra-indicates cisplatin use (Perez and Brady).   
There is renewed interest in the role of induction chemotherapy as part of sequential 
treatment in the concurrent chemotherapy with radiotherapy schedule for advanced larynx 
cancer (Leibel and Phillips, 2010). Results of ongoing randomised trials comparing induction 
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chemotherapy followed by chemotherapy plus radiotherapy versus chemotherapy plus 
radiotherapy alone are awaited (Leibel and Phillips, 2010). 
b) Radiation Therapy technique for advanced stage III & IV disease 
For advanced stage lesions the incidence of lymph node involvement increases to 20-30% 
therefore fields are larger to cover lymph nodes which include the jugulodigasric (level IIA & 
IIB nodes) and middle jugular lymph nodes (level III nodes) shown in Figure1.1.3 above. The 
treatment fields are depicted in the DRR’s (Digitally Reconstructed Radiographs) from 
CMJAH figure1.2.2 (large lateral field) and figure 1.2.3 (lateral off-cord field) the posterior 
border is moved forward after 40Gy/20# radiation dose to come off the spinal cord. The 
inferior jugular nodes (level IV nodes) are included in a separate low neck portal figure1.2.4 
(anterior neck field). Lead (Pb) shield is introduced in the centre after 40Gy/20# radiation 
dose to shield the spinal cord figure1.2.5. Dose fractionation schedule for T3/T4 lesion is 
70Gy/35# (2Gy per fraction) daily (Perez and Brady). 
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Figure 1.2.2 Lateral large field for treating advanced stage cancer of the larynx. Extent of field indicated by bold red line.  
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Figure 1.2.3 Lateral off-cord field (bold red line). The posterior border is moved forward to come off the spinal cord.   
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Figure 1.2.4 Anterior neck field for advanced cancer of the larynx. Superior border is matched to lateral fields shown in 
Figure 1.2.2 & Figure 1.2.3 above. Extent of field indicated by bold red line.  
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Figure 1.2.5 Anterior neck field with lead (Pb) shield in the centre. Extent of field indicated by bold red line.  
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1.3 Factors that negatively influence treatment outcome 
Overall treatment time is a very important factor determining outcome of head and neck 
cancers treated with radiotherapy. Head and neck cancers are fast growing tumours with rapid 
proliferation and treatment with radiation can trigger surviving cells (clonogens) in the 
tumour to divide faster than before i.e. accelerated repopulation (Hall EJ, 2000). The 
clonogen repopulation accelerates at about 28 days after initiating radiotherapy and local 
control is reduced by about 0.4 to 2.5 % for each day that the overall treatment time is 
prolonged  (Hall EJ, 2000).  
The influence of the number of fractions and overall treatment time on local control and late 
complication rate in advance T3/T4 (N0M0) squamous cell carcinoma of the larynx was 
retrospectively assessed by (Hliniak A et.al, 1983). After a minimum of 3 years follow-up 
310 patients were assessed by the same laryngologists .Local control was achieved in 50% of 
patients and 21 patients who had tumour control, developed severe late complications such as 
necrosis or laryngeal oedema during the follow-up period. Overall treatment time was the 
predominant factor as patients with longer overall treatment time had more late complications 
and poorer local control. 
(Overgaard J et.al, 1998) also compared conventional and split-course radiotherapy as 
primary treatment in carcinoma of the larynx in 308 patients treated to 57Gy or 60Gy. Results 
showed that split-course was associated with a significantly reduced therapeutic ratio and did 
not improve tumour control while the severity of late complications increased. The 3-week 
pause in the radiation therapy did not reduce late complications, and the tumour response did 
not improve despite a 12-Gy increase in total dose. This indicates a significant repopulation 
and increase of number of clonogenic tumour cells during the pause. It is evident from these 
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studies that splitting treatment and increasing overall treatment time lead to poorer tumour 
control and increased late complications. 
Waiting time prior to radiotherapy is a major problem in many radiotherapy centres and has a 
negative impact especially for rapidly growing head and neck cancers.(Jensen A.R et al, 
2007) looked at tumour progression in waiting time for radiotherapy in head and neck cancer. 
They assessed the change in tumour volume on CT scans done during the waiting time and 
found that within an average of 4 weeks the majority of patients developed significant signs 
of tumour progression, 62% had measurable increase in tumour volume, 20% developed new 
lymph nodes and 10% progressed in TNM stage. 
Effects of treatment delay on outcome of patients with early stage head and neck carcinoma 
receiving radical radiotherapy were assessed in a retrospective study by (Fortin A et al, 
2002). They found that treatment delay of more than 40 days was significantly associated 
with increased risk of local and neck failure and poorer survival relative to patients treated in 
less than 30 days. They concluded that radiotherapy for squamous cell carcinoma of the head 
and neck should be started preferably within 20-30 days after evaluation by radiation 
oncologist. 
(Hansen O et al, 2005) assessed the relationship between the duration of symptoms before the 
start of radiotherapy and treatment outcome in stage I – III glottis cancer. They found that 
one month delay from onset of symptoms to start of radiotherapy was equivalent to a 4.5 % 
decrease in recurrence free survival.  
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1.4 Palliative Radiotherapy  
 A proportion of patients with head and neck cancers are not candidates for curative therapy 
because of advanced stage of disease, medical comorbidities, performance status e.g. ECOG 
performance status (appendix 2) or a combination of these factors. Although the prognosis for 
these patients is poor, palliative radiotherapy has been widely used to provide symptom 
relief. 
(Christiaan M et al 2011), retrospectively analysed palliative radiotherapy in newly diagnosed 
head and neck carcinoma and found that 82 % of their population had treatment response to 
palliative radiotherapy, 12 % had no response or progressive disease while 6 % had mixed 
responses. Delivered radiation dose was the only statistically significant predictor of 
treatment response and overall survival. In this study the median radiation dose was 50Gy 
and the median fraction number was 20. 
Laryngeal cancer even in advanced stages has a relatively high cure rate if managed 
appropriately hence there’s limited data on palliative treatment for laryngeal cancer.  
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2. CURRENT STUDY 
2.1 Background 
Most of the studies that demonstrated the feasibility of larynx preservation with 
chemotherapy plus radiotherapy for advanced cancer of the larynx were done in more 
developed countries than South Africa where resources are readily available. At the time we 
started the treatment it was not known how patients in our institution Charlotte Maxeke 
Johannesburg Hospital (CMJAH) would tolerate the recommended concurrent chemotherapy 
plus radiation therapy. 
 Most of our patients are of low socio-economic background as there is increasingly high 
unemployment rate of 25.2% (Statistics South Africa, 2013) they have poor nutritional 
support.  In South Africa resources are limited as one radiation oncology centre in 
Johannesburg serves more than 10 hospitals for treatment of all types of cancer (personal 
communication with Miss Salome Liebenberg -departmental database collector).Patients 
travel long distances for radiation therapy from different hospitals e.g. patients from as far as 
Mafikeng (292km) in the north west province referred by Klerksdorp Hospital to CMJAH for 
radiation therapy (Map data ©2013 AfriGIS (Pty) Ltd, Google).    
Resource constraints within the hospital as there are no dedicated oncology facilities, 
oncology patients have to wait with medical and surgical patients for investigations such as 
pathology and imaging. This can delay the preparation, staging and planning of therapy and 
the time needed to complete treatment for each patient of +/- 6 weeks also lead to long 
waiting times before treatment can be commenced.  
In view of all the problems identified in our department of Radiation Oncology at CMJAH, 
this study was done to assess how patient’s treatment is affected. 
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 2.2 Study Objectives 
 To describe the demographics of the population 
 To compare characteristics of patients in the different treatment groups  
 To assess waiting times, treatment completion rates and overall treatment time for all 
patients in the study group. 
 To describe outcomes of patients at last follow up and survival for different stages of 
disease.  
2.3 Material and Methods  
 
The study was done at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) 
department of Radiation Oncology. The hospital is a tertiary academic institution that 
receives referrals from primary and secondary health institutions around Gauteng.  
The department of Radiation Oncology at CMJAH sees about 70-80 new patients with cancer 
of the larynx each year (personal communication with Miss Salome Liebenberg -
departmental database collector). Patients treated with radiotherapy for cancer of the larynx 
with or without chemotherapy between the year 2007 and 2009 were retrospectively assessed. 
Males and female patient were included in the study. Early, stage I and stage II disease and 
advanced, stage III and stage IV disease were assessed.  
The sample included patients who were treated with radical intent which included:               
(1) concurrent chemotherapy plus radiotherapy, (2) radical radiotherapy alone,                                    
and patients treated with palliative intent which included: (3) patients with disease 
progression ‘treatment intent changed from radical to palliative’ and, (4) patients with 
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advanced disease i.e. on first assessment at the multidisciplinary meeting with ENT surgeons 
were deemed unfit to undergo radical treatment. 
Some patients at initial assessment were planned for radical treatment but their condition or 
ECOG (appendix 2) performance status deteriorated while they wait for treatment and their 
treatment is changed to palliative. The waiting time was calculated from the date when 
patient was first seen in the radiation oncology department to the date that treatment was 
started. All patients were staged using the AJCC 2002 cancer staging manual 6
th
 edition 
(Hansen EK; Roach M, 2010) as the patients in the study were assessed before the new AJCC 
2010 manual 7
th
 edition (Hansen EK; Roach M, 2010).  
 The AJCC 2002 (TNM and Group staging) was republished with no changes in the AJCC 
2010 manual 7
th
 edition (Hansen EK; Roach M, 2010) as well as the group staging shown in 
table 1.1.  
Since radiation therapy is given daily Monday to Friday patient’s treatment charts were 
looked at to see if there was a gap in treatment dates. If a gap was found then the doctor’s 
notes on that date were checked to see if the patient’s treatment was split because of 
treatment toxicity (RTOG/EORTC) radiation toxicity grading system (appendix 3). 
 Patients who did not have treatment interruption due to toxicity were excluded from the 
analysis of toxicity. All files were checked to see if treatment was completed as prescribed 
and the total dose administered was noted, for radical cases chemotherapy cycles given were 
noted. Follow-up time was calculated from the date of last treatment to the date last seen in 
the clinic for review. Outcome of patient when last seen (whether symptoms improved or not 
or patient demised) was documented. Patients who were not seen at our clinic since 
completion of treatment were entered as lost to follow-up.  
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2.3.1 Exclusion criteria    
1) Patients who had surgery more than just a tracheostomy e.g. partial or total 
laryngectomy prior to radiation therapy as the study only assessed larynx preserving 
treatment approach. 
2) All patients with cancer of the larynx who were seen at our clinic during the time 
period year 2007-2009 but never received any radiotherapy. 
2.3.2Treatment Protocol CMJAH 
Radiation Therapy 
 Treatment and side effects thereof are explained to the patient and informed 
consent is obtained. 
 All patients treated with radical intent were sent for dental assessment and 
clearance prior to treatment 
 Patients are immobilised in a mask in supine position and neck in extension. 
 CT scan of head and neck is done with patient  in treatment position 
 Fields are delineated according to extent of disease as in figure 2.1 for early 
stage I & II disease and figures 2.2 to 2.5 above for locally advanced stage III 
& IV disease 
  Photons energy of 6MV (Megavoltage) used 
 The posterior neck is boosted with electrons 10Gy in 5 fractions 
 If patient had a tracheostomy the stoma is boosted with 20Gy in 10 fractions.  
 The total radiation dose for T1/T2 disease is 62Gy/31# to 66Gy/33# and for 
T3/T4 disease is 70Gy/35#. During radiation therapy patients were assessed 
for treatment toxicity which is graded using the RTOG/EORTC radiation 
toxicity grading system (appendix 3). 
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Chemotherapy  
Cisplatin 70mg/m2 is given 3 weekly to patients treated with radical intent. Before 
administration bloods are taken for FBC (WCC>3.000 cells/µl, HB=12g/dl as long as not < 
10g/dl, Plt >100 cells/µl), urea and creatinine, magnesium, calcium. Creatinine clearance is 
calculated using the Cockcroft and Gault formula and if >60mils/min chemotherapy 
continues, if < 60mils/min chemotherapy is not given.  
 Cockcroft and Gault formula (O.O. Faluyi et.al) 
 140-age(years) x weight(kg) x 1.23 / creatinine (mmol) for males  
 140-age (years) weight(kg) x 1.04 / creatinine (mmol) for female 
 Each patient is given pre-hydration using normal saline calcium, magnesium and potassium 
prior to chemotherapy. Anti emetic drugs including: 5-hydroxytryptamine-3 (5HT3) receptor 
antagonist, i.e. Granisetron or Ondansetron which significantly reduces acute cisplatin-
induced emesis are given. One week after chemotherapy the above mentioned blood tests are 
repeated and electrolytes are corrected. The department has a dietician who assists and 
monitors nutritional status of patients and provide nutritional support during treatment. 
2.4 Data Analysis 
Data was analysed using descriptive statistics with frequencies + percentages for categorical 
data and means or medians and standard deviations or ranges for numerical values. The 
comparison of waiting times amongst treatments was done using the independent sample test. 
The equality of variances assumption was tested using the Levene’s test for equality of 
variances before the waiting time comparison was made. Survival was calculated using the 
Kaplan-Meier method. 
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3. STUDY RESULTS 
The department of Radiation Oncology at CMJAH saw 203 new patients with cancer of the 
larynx between the year 2007 and 2009. Only 106 patients were eligible for analysis as other 
patients were excluded. Sixteen patients were excluded because they had partial /total 
laryngectomy prior to radiotherapy and the other 81 patients were excluded because did not 
receive radiotherapy. 
Males made up the majority of the population 91.5% versus 8.5% for females. The mean age 
at presentation was 58.6 years (standard deviation of 10.05). Of the 106 patient included in 
the study the majority 67% presented with stage IVa disease, 14% of  patients had stage IVb, 
13% had stage III, and very few had stage I and II disease 4% and 2% respectively (Figure 
3.1). 
 
Figure 3.1 Distribution of subjects in the study with respect to the stage of disease. 
In our department we have two main treatment groups based on the treatment intent i.e. 
Radical (curative) intent or Palliative intent. When assessing characteristics of patients in 
these two treatment groups we discovered that both groups were further divided into two 
groups which gave a total of four treatment groups. 
1 2 3 4a 4b 
4% 2% 
13% 
67% 
14% 
Stage Grouping 
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The patients treated with radical intent were divided into Radical radiotherapy with 
concurrent chemotherapy and Radical radiotherapy alone. The characteristics of patients 
treated with palliative intent further divided this group into patients who had disease 
progression while awaiting treatment, therefore their treatment intent changed from radical to 
palliative and those who presented with advanced disease at first visit and required palliation 
from the start. Figure 3.2 shows the four different treatment groups and the percentage of 
patients treated.   
     
 
Figure 3.2 Treatment groups and percentage of patients treated 
 
A total of 42.5% of the patient population were treated with palliative radiotherapy divided 
between those with progressive disease (13%) and those with advanced disease (29%) at 
initial assessment. 
32% 
29% 
26% 
13% 
Chemo Radiation 
Advanced Disease 
Radiation only 
Progressive Disease 
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Most (57.5%) of the population were treated with a radical course of radiotherapy with an 
almost equal split between those receiving concurrent chemotherapy and radiotherapy and 
those receiving radical radiotherapy alone. 
Table 3.1 Demonstration of Stages of disease between the four treatment groups. 
 
 
 
 
 
 
 
 
 
 
 
  
Rt= Radiotherapy                            (pt no) = patient numbers 
 
All patients with early stage I and II disease received radical radiotherapy without 
chemotherapy. Most of the patients with stage III disease were treated with radical intent and 
majority of them received radiotherapy alone (7) only a few received chemotherapy with 
radiotherapy (4). Reasons for patients with stage III disease not receiving chemotherapy were 
not clearly documented. In some cases low CD4 count was documented as reason for not 
giving chemotherapy but this was not always documented in other files. Since an HIV test 
was not an entry requirement for this study data was collected if documented but was not 
analysed. Of those with stage III disease treated with palliative intent only one patient was 
                                     Treatment            
 Chemo/Rt Palliative 
(advanced
disease)   
Radical Rt 
only 
Palliative 
 (disease 
progress) 
Total  
 (pt no) & 
%     
Group 
Stage 
I 0 0 4 0 4 (4%) 
II 0 0 2 0 2 (2%) 
III 4 2 7 1 14 (13%) 
IVA 27 20 13 11 71 (67%) 
IVB 3 9 1 2 15 (14%) 
TOTAL (pt no) 
TOTAL ( % ) 
               34 
            32% 
             31 
          29% 
                27 
             26% 
              14 
          13% 
     106 
  100% 
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due to disease progression while awaiting treatment while the other two had poor 
performance status at initial assessment. 
In patients with stage IVa (total 71) majority (40) was treated with radical intent (chemo/Rt 
and Radical Rt alone) while (31) received palliative treatment. Those with stage IVb (total 
15) majority (11) received palliative treatment and only 4 patients were treated with radical 
intent. Of the total population in the study stage IVa and stage IVb make up for the most of 
patients treated with palliative intent due to the advanced stage of disease and or poor 
performance status. 
The waiting time was calculated from the date when patient was first seen in our department 
to the date that treatment was started. Patient delays prior to being seen at our hospital e.g. 
waiting for histology results from referring hospitals were not included since they are out of 
our control. The overall mean waiting time for treatment in the study group was 98.5 days. 
When comparing the waiting time for the different treatment groups, in the group that was 
treated with palliative intent those patients that had disease progression had a longer waiting 
time compared to those that had advanced disease at presentation i.e. 187.9 days versus 46.3 
days standard deviation of 186.1 (p=0.014) which was statistically significant. Patients with 
advanced disease at presentation have a shorter waiting time because their treatment planning 
technique is less sophisticated and their treatment time is shorter than radical cases therefore 
their waiting list is shorter.  
The waiting time for patients with disease progression was not statistically significant when 
compared with patients who were treated with radical intent i.e. Radiation alone and Chemo-
Radiotherapy, 187.9 days versus 97.8 days and 109.8 days ( p=0.095 and p=0.174). Since the 
patients who had disease progression are those who were deemed curable (with good 
performance status) at initial assessment their waiting time was not statistically different from 
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the waiting time of other patients treated with curative intent Radiation alone and Chemo-
Radiotherapy.  
Most of the population (84%) completed treatment (radiation fractions) as prescribed while 
16% did not. Of those that were treated with concurrent chemotherapy plus radiotherapy 
2.9% completed 3 cycles of chemotherapy, 32.4% received 2 cycles of chemotherapy and 
64.7% received only 1 cycle of chemotherapy. Some patients did not receive their 2
nd
 or 3
rd
 
cycle of chemotherapy due to low creatinine clearance other patients reasons for not 
completing chemotherapy was not documentation in their medical records. 
A small number of patients (6.6%) had treatment interrupted by the doctor due to toxicity and 
five patients had a treatment break of less than 15days while the other 2 had a treatment break 
for more than 15 days. Those patients who had a longer treatment break had a longer overall 
treatment time and we looked at how that influenced their outcome (table 3.2). 
Table 3.2 -Patients with more than 2 weeks treatment interruption (planned break) 
Patient Stage Split 
duration 
Reason for break Outcome 
1) 
 
 
 
T4N2 
i.e. 
Group 
stage 
IVB 
42days 
 
 
 
Severe moist 
desquamation of the skin 
after 50Gy/25# 
RTOG grade 3 toxicity 
 
Treatment schedule 
adjusted to compensate 
for split and dose 
completed. Patient had 
neck fibrosis on follow-up 
2) 
 
 
T3N3 
i.e. 
Group 
stage 
IVB 
 
27days 
 
 
Developed obstructive 
airway symptoms 
treatment split for 
tracheostomy to be done 
 
RTOG grade 4 toxicity 
Treatment schedule 
adjusted to compensate 
for split and dose 
completed. Patient had 
disease progression 
biopsy proven lesion on 
base of tongue. 
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Outcome of patient population at last follow-up 
 56 patients (52.8%) reported improvement of symptoms when last seen at the clinic.  
 26 patients (24.5%) reported no improvement or worsening of symptoms. Majority of 
these patients were treated with palliative course of radiation therapy as they had 
advanced incurable disease or they were in a poor ECOG status (appendix 2). 
 18 patients (17%) were lost to follow-up i.e. were not seen at our clinic since 
completion of treatment therefore not known whether symptoms improved or not. 
 6 patients (5.7%) demised during or soon after treatment completion. 
 
Figure 3.3 Survival in days on last follow-up for different stages of disease (Kaplan 
Meier) 
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Survival outcomes were measured from the end of radiotherapy to 1year and 2 years follow 
up for all the stages of disease. Most of the patients at 2 years follow up were not seen at our 
clinic either they were lost to follow up or possibly demised. None of the patients with stage I 
disease which represented 4 % of the population were seen in our clinic at 2 years follow-up 
and only 50 % of those with stage II were seen at 2 years post treatment. Attempts to call 
these patients using contact numbers on patient’s records were unsuccessful. Patient’s 
identity numbers were not recorded on most patients files to enquire with home affairs 
whether patients had demised or not. 
Patients with advanced stage disease including stage III, IVa and stage IVb who represented 
the majority of the patients in the study group had survival of less than 20 % at 2 years 
follow-up. Although stage IVb seems to have done better than stage IVa at 1 year follow-up 
the graphs come closer together between 1 and 2 years follow-up on the Kaplan Meier and 
the difference between the two survival outcomes was not statistically significant with the log 
rank (Mantel-Cox) of 0.628  
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4. Discussion 
Most of the patients seen at our institution during the study period presented with advanced 
stage of disease stage IVA being the most common followed by stage IVB and stage III. 
Early stage I & II represented a minority of the total population. Males were more affected 
than females which correlated with what Perez and Brady 2008 suggested. 
Waiting time prior to radiotherapy remains a major problem in most radiation oncology 
centres. In our study we found that our overall mean waiting time was 98.5 days i.e. from the 
date when patient was first seen by the oncologist in our department to the date that treatment 
was started. This is well in excess of that recommended by the standard of care and is 
reflected in the literature as a worsening prognosis. Fortin A et al, 2002 in their study found 
that treatment delay of more than 40 days was associated with poorer survival and Jensen AR 
et al, 2007 also found that 62 % of their patients had increase in tumour volume at 4 weeks 
waiting time. They concluded that radiotherapy for squamous cell carcinoma of the head and 
neck should be started preferably within 20-30 days after evaluation by radiation oncologist. 
We could not evaluate increase in tumour volume in majority of patients during our waiting 
time as CT scans were not routinely done due to lack of imaging resources. 
Disease progression was defined as change in treatment intent from radical to palliative 
treatment. This was seen in 13% of the study population which is of concern as these are 
patients who would have received curative treatment if treatment was initiated earlier. We 
looked at whether patients with disease progression had a longer waiting time for treatment 
when compared with other patients treated with radical curative intent. Their waiting time 
was not statistically significant when compared with patients who were treated with radical 
intent i.e. Radiation alone and Radiotherapy with concurrent chemotherapy, 97.8 days and 
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109.8 days respectively versus 187.9 days for disease progression group ( p=0.095 and 
p=0.174). The study therefore failed to show that their disease progression was as a result of 
a longer waiting time. This is probably a result of insufficient numbers to reach statistical 
significance. 
The disease progression group however had a statistically significant longer waiting time 
when compared with other patients treated with palliative intent due to advanced disease at 
presentation i.e. 187.9 days versus 46.3 days standard deviation of 186.1 (p=0.014). This is 
expected as in our department palliative patients are treated sooner because their treatment 
technique is not sophisticated and does not require specialised treatment planning.  
 A significant number of our patients (29%) were considered unsuitable for curative treatment 
at initial assessment. This is a concern in that many patients that could be potentially cured or 
have a better prognosis if they were seen with earlier stage disease and with better 
performance status. This reflects a lack of resources to detect and diagnose oncology 
problems in the communities where the patients are living and a lack of resources and delays 
with imaging, pathology, referral and transport in the public health environment that the 
CMJAH functions. 
Treatment completion rates and overall treatment time for patients in the study group were 
assessed. We looked at patients who had their treatment interrupted by the doctor due to 
toxicity using the RTOG toxicity grading as one of the aims was to assess how patients 
tolerated treatment. Patients who had treatment interruption on their own were not assessed as 
some missed treatment because of social reasons not toxicity e.g. lack of money to come for 
treatment. Although these reasons were not well documented in some files they are common 
causes for patients to default during treatment and at follow-up.  
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Seven patients (6.6% of the population) had planned treatment interruption and most of them 
had a break of less than 15 days while two patients had a treatment break longer than 15 days. 
Reasons for a longer break were assessed for those patients and shown in table 3.2. The 
results of longer overall treatment time for our patients were in keeping with results from 
(Hliniak A et al, 1983 and Overgaard J et al, 1998) as one patient had disease progression 
while the other patient had severe neck fibrosis. Longer overall treatment time had poor local 
tumour control and did not reduce the severity of late complications.   
Assessment of treatment completion rates for the total population showed that sixteen percent 
of the patients did not complete treatment as prescribed. Of the radical cases only one third of 
them received the recommended approach of concurrent chemotherapy plus radiotherapy. 
Most of the patients in the chemotherapy plus radiotherapy group only received 1 cycle of 
chemotherapy instead of the recommended 3 cycles. Reasons for not completing 
chemotherapy were not clearly documented in most patient records, in some patients low 
creatinine clearance after the first cycle was noted while in some patients low CD4 count was 
documented. HIV test was not recorded for most patients and since it was not one of the entry 
requirements for this study, data was collected if documented but was not analysed.   
 In the RTOG 91-11 study which established the use of concurrent cisplatin and radiotherapy 
as the superior non surgical larynx preserving strategy patients received 3 cycles of 
chemotherapy with radiotherapy (Forastiere AA et al 2003). Since most of our patients did 
not receive treatment according to the recommended schedule our results could not be 
compared with those in other studies for local control or survival.   
Due to lack of resources response to treatment could only be judged by change in symptoms 
and clinical examination e.g. (IDL) indirect laryngoscope for patients who were followed up. 
If patients had persistent symptoms or had suspicious IDL examination at follow- up they 
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were then reviewed with ENT surgeons to do direct laryngoscope and a follow up CT scan. 
Post treatment CT scans were not routinely done for all patients. Majority of the patients 
(52.8%) reported improvement of symptoms. 
Survival outcomes were measured at 1 year and 2 years follow up. At 1year patients with 
stage I disease and stage II had 50% follow up, those with stage III had 45% follow up while 
IVb had 20% and stage IVa had less than 20% follow up. At 2 years none of the patients with 
stage I disease came for follow up and 50% of patients with stage II disease were followed 
up. Only 10% of patients with stage III, IVa and IVb disease were followed up at 2 years. 
The difference in survival at last follow-up was not statistically significant for advanced stage 
disease i.e. stage III, IVa and IVb with the log rank (Mantel-Cox) of p=0.628.      
5. Study Limitations 
 
This is a retrospective study therefore the information recorded in patient’s files was not 
consistent as patients were seen by different doctors who recorded events during treatment 
differently. In most cases functional outcome and quality of voice post treatment was not 
recorded therefore we were unable to assess percentage of functional larynx preservation in 
our study.  
Disease progression was defined as change in treatment intent from radical to palliative 
treatment. Those patients who could have progressed in the T-N-M stage but were still fit for 
radical treatment could not be assessed as restaging is not routinely done at the start of 
treatment after waiting time. Our results for patients with disease progression are incomplete.   
A significant number of patients (81patients) seen at our institution during the study period 
had to be excluded because they were not treated and the reasons for not treating were 
unclear. There was quite a high percentage (17%) of patients with no follow up post 
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treatment. Response to treatment could only be judged by change in symptoms and (IDL) 
Indirect Laryngoscope examination findings for those patients who were followed up, post 
treatment CT scans were not routinely done to assess response. As patients were examined by 
different doctors at follow up, there was lack of consistency in documenting IDL findings in 
patient’s records.     
We could not compare our results of patients treated with the recommended radical 
concurrent chemotherapy plus radiotherapy with results from other studies as majority of our 
patient (64.7%) in that treatment arm received suboptimal chemotherapy. Survival outcomes 
could only be measured for patients who came for follow up post treatment. 
 
6. Conclusion 
  
Cancer of the larynx is a significant disease burden in patients referred to CMJAH. Most 
patients (81%) presented with advanced stage IV disease (IVa + IVb combined). A 
significant number of these have disease that is potentially salvageable but delays in 
treatment delivery are impairing the treatment efficiency. The overriding conclusion in this 
study was that patients with Head and Neck cancer referred to CMJAH are being 
inadequately treated with regards to the standards of care as published in evidence based 
literature. The causes are multi-factorial and relate to the overall functioning of the health 
services in Gauteng province.  
Our institution Charlotte Maxeke Johannesburg Academic hospital as the one centre 
rendering service to many hospitals for treatment of cancer is under resourced for patient 
volumes. Waiting time prior to radiotherapy is a major problem in our institution as our 
overall mean waiting time was 98.5 days which is more that the preferred 20-30 days waiting 
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time for head and neck cancers (Jensen AR et al). Although the study could not shown that 
the patients who had their treatment intent changed from radical to palliative i.e. disease 
progression had a statistically significant longer waiting time compared to patients treated 
with radical intent, the disease progression group had a mean waiting time of 187.9 days 
which is almost double our overall mean waiting time of 98.5 days. This is a call for concern 
for the department to try and reduce treatment waiting times. The causes for delays are multi-
factorial and include referring patients for dental assessment and clearance after the initial 
assessment in the oncology centre, imaging for staging and booking patients for 
immobilisation and in some instances there is lack of material used for immobilisation which 
further increase the waiting before treatment planning can be done.     
Lack of diagnostic and radiological capacity resulted in us not having measurable tumour 
volume changes to properly evaluate disease progression during waiting time and to evaluate 
response to treatment at follow-up. Lack of resources again may partly be responsible for our 
poor patient follow up as they have to travel long distances after treatment to be followed up. 
With the increase in the unemployed rates in South Africa of 25.2% shown in recent 
(Statistics South Africa survey, 2013), patients cannot afford travelling expenses.  
Although induction chemotherapy followed by radiotherapy versus concurrent chemotherapy 
plus radiotherapy has been extensively studied and the latter was found to be superior for 
larynx preservation, this study has shown that most of our patients do not receive the 
concurrent chemo-radiotherapy as recommended. A prospective study to evaluate whether, 
induction chemotherapy given during the waiting time in our institution especially to patients 
with advanced stage of disease but still in good (ECOG status) would not reduce the number 
of patients who have disease progression and allow more patients to be treated with radical 
instead of palliative intent would be useful for our setting.  
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In view of the available evidence that suggest that increasing the dose per fraction from 2Gy 
to 2.25Gy for patients with early glottis carcinoma showed superior local control and further 
shortened overall treatment time (Yamazaki H et al, 2006), protocols in our department need 
to be reviewed. Patients with early disease should be treated with a shorter regimen and a 
higher dose fractionation schedule of 2.25Gy as this will also reduce our overall treatment 
time and waiting time for treatment while improving local control.  
It is important that treatment protocols are guided by literature from results of large 
randomised studies but they should also be adjusted according to circumstances of individual 
institution. For our institution it would be important to increase the number of patients that 
are treated with radical intent. 
To win the battle and improve our results South Africa’s oncology services need to improve 
so that more centres that can treat cancer are accessible to patients promptly. Dedicated 
oncology hospitals would be of benefit where cancer patients would not have to wait for 
investigations with other medical or surgical patients. Multiple oncology centres with 
adequate and well maintained equipment such as radiology and radiation treatment machines 
to cope with patient loads are needed.  
Improving the unemployment rate, therefore improving patient’s socioeconomic status and 
nutritional status would also have a big impact in on our cancer patients. Education is also a 
key to success and will help patients with understanding their disease and the need for 
treatment which will yield better treatment compliance and better follow-up after treatment 
completion.      
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Appendix 1: 
AJCC (TNM) Staging for Laryngeal Cancer 
Supraglottis 
T1                    tumor limited to one subsite of supraglottis with normal vocal cord        
                        mobility  
T2                       tumor invades mucosa of more than one adjacent subsite of  
                            supraglottis or glottis or region outside the the supraglottis  
                            (e.g. mucosa of base of tongue , vallecula, medial wall of  
                            pyriform sinus ) without fixation of the larynx                            
T3                       tumor limited to larynx with vocal cord fixation and/or invades any 
                            of the following: postcricoid area, preepiglottic tissues, paraglottic  
                           space and/or minor thyroid erosion. 
T4a                     tumor invades through the thyroid cartilage and/or invades beyond  
                           the larynx (e.g. trachea,soft tissues of the neck including deep 
                           extrinsic muscles of the tongue, strap muscles,thyroid or esophagus 
T4b                     tumor invades prevertebral space, encases carotid artery or invades 
                           mediastinal structures  
Glottis 
T1                       tumor limited to vocal cord(s) may involve anterior or posterior 
                           commissure with normal mobility  
T1a                     tumor invades one vocal cord 
T1b                     tumor invade both cord cords 
T2                       tumor extends to supraglottis, and/or subglottis and/or with impaired 
                           vocal cord mobility  
T3                       tumor limited to the larynx with vocal cord fixation and/or invades 
                           paraglottic space and/or minor thyroid cartilage erosion (e.g. inner 
                           cortex) 
T4a                     tumor invades through the thyroid cartilage and/or tissues beyond 
                           the larynx ( trachea, soft tissues of the neck including deep extrinsic 
                          muscles of the tongue, strap muscles, thyroid or esophagus 
T4b                    tumor invades prevertebral space , encases carotid artery, or invades 
                          mediatinal structures     
Subglottis 
T1                     tumor limited to the subglottis 
T2                     tumor extends to vocal cord(s) with normal or impaired mobility 
T3                     tumor limited to larynx with vocal cord fixation 
T4a                   moderately advanced local disease. Tumor  invades cricoid or thyroid               
                         cartilage and or invades beyond the larynx ( e.g. trachea , soft tissues                            
                     of neck including deep extrinsic muscles of the  tongue, strap muscles 
                         thyroid, or esophagus. 
T4b                  very advanced local disease. Tumor invades prevertebral space , encases  
                         carotid artery, or invades mediastinal structures 
Regional Lymph Nodes 
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N0                    no regional lymph node metastasis 
N1                    metastasis in a single ipsilateral lymph node < 3cm in greatest dimension 
N2a                  metastasis in a single ipsilateral lymph node > 3cm but < 6cm in greatest  
                        dimension 
N2b                 metastasis in multiple ipsilateral lymph nodes, none > 6cm in greatest 
                       dimension 
N2c                 metastasis in bilateral or contralateral lymph nodes, none > 6cm in greatest 
                       dimension 
N3                  metastasis in a lymph node > 6cm in greatest dimension                                                      
Distant Metastases 
Mx                   Distant metastases cannot be assessed                 
M0                 No distant metastases  
M1                 Distant metastases 
American Joint Committee on Cancer manual 7
th
 edition 2010 (Leibel and Phillips, 2010)  
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Appendix 2 
: ECOG (Eastern Cooperative Oncology Group) Performance Status   
 
Grade                           ECOG 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and able 
to carry out work of a light or sedentary nature, e.g. light house 
work, office work 
2 Ambulatory and capable of all self care but unable to carry out any 
work activities. Up and about more than 50% of waking hours 
3 Capable of only limited self care, confined to bed or chair more 
than 50% of waking hours 
4 Completely disabled. Cannot carry on any self care. Totally 
confined to bed or chair 
5 Dead 
Oken M et al (1982)   
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Appendix 3:   
: RTOG/EORTC Acute Radiation Toxicity Grading for Larynx Treatment 
Tissue Grade 1 Grade 2 Grade 3 Grade 4 
Skin 
 
 
Follicular, faint 
or dull erythema/ 
epilation/ dry 
desquamation/ 
decreased 
sweating 
Tender or bright 
erythema, patchy 
moist 
dequamation/ 
moderate edema 
 
Confluent, moist 
desquamation 
other than skin 
folds, pitting 
edema 
Ulceration, 
haemorrhage, 
necrosis 
 
Mucous 
membrane 
 Injection/ may 
experience mild 
pain not requiring 
analgesic 
 
 
 
Patchy mucositis 
that may produce 
an inflammatory 
serosanguinous 
discharge/ may 
experience 
moderate pain 
requiring 
analgesia 
Confluent 
fibrinous 
mucositis/ may 
include severe 
pain requiring 
narcotic 
 
Ulceration, 
haemorrhage, 
necrosis 
 
Salivary 
glands 
Mild mouth 
dryness/ slightly 
thickened saliva 
may have slightly 
altered taste such 
as metallic taste/ 
these not 
reflected in 
alteration in 
baseline feeding 
behaviour, such 
as increased use 
of liquid with 
meals  
 
 
Moderate to 
complete dryness/ 
thick, sticky 
saliva/ markedly 
altered taste 
 
 
 
None 
 
 
 
Acute salivary 
gland necrosis 
Pharynx and 
esophagus 
Mild dysphagia 
or odynophagia/ 
may require 
topical anesthetic 
or non-narcotic 
analgesisics/ may 
require soft diet 
Moderate 
dysphagia or 
odynophagia/ may 
require puree or 
liquid diet 
Severe dysphagia 
or odynophagia 
with dehydration 
or weight loss 
>15% from 
pretreatment 
baseline requiring 
NG feeding tube, 
Complete 
obstruction, 
ulceration, 
perforation, fistula 
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IV fluids or 
hyperalimentation  
 
Larynx Mild or 
intermittent 
hoarseness/ 
cough not 
requiring 
antitissive/ 
erythema of 
mucosa  
Persistent 
hoarseness but 
able to vocalize/ 
referred ear pain, 
sore throat, patchy 
fibrinous exudates 
or mild arytenoids 
edema not 
requiring narcotic/ 
cough not 
requiring 
antitussive 
Whispered 
speech, throat 
pain or referred 
ear pain requiring 
narcotic/ 
confluent 
fribrinous 
exudates, marked 
arytenoids edema   
Marked dyspnea, 
stridor or 
hemoptysis with 
tracheostomy or 
intubation 
necessary 
Ear Mild external 
otitis with 
erythema, 
pruritus, 
secondary to dry 
desquamation not 
requiring 
medication. 
Audiogram 
unchanged from 
baseline   
Moderate external 
otitis requiring 
topical 
medication/ serous 
otitis media/ 
hypoacusis on 
testing only 
Severe external 
otitis with 
discharge or 
moist 
desquamation/ 
symptomatic 
hypoacusis/ 
tinnitus, not drug 
related   
 
 
Deafness 
                                                                  HAEMATOLOGICAL 
WBC 3.0 - <4.0 2.0 - <3.0 1.0 - <2.0 <1.0 
Platelets 75 - <100 50 - <75 25 - <50 <25orspontaneous 
bleeding 
Hgb 11 - 9.5 <9.5 – 7.5 <7.5 – 5.0(packed 
cell transfusion 
required) 
None 
Neutrophils 1.5 - <1.9 1.0 - <1.5 0.5 - <1.0 <0.5 or sepsis 
Cox JD et al (1995)  
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Appendix 4: 
: Summary of studies showing local control and larynx preservation with 
Radiation Therapy and Surgical salvage for T1 & T2 Ca glottis   
n/n = number of patients salvaged/ number of patients who underwent salvage treatment 
 
 
 
 
 
Reference Patients 
n 
Local control Larynx 
Preservation 
Surgical Salvage  
n/n 
Mendenhall  et al 
(2001) 
291 98 95 18/18 
Mittal et al (1983) 177 96 90 23/30 
Wang et al (1990) 723 97 90 46/59 
Le et al (1997) 315 97 89 41/52 
Johansen et al (1990) 358 94 91 40/55 
Amornmarn et al 
(1985) 
86 99 92 6/7 
Spector et al (1999) 104 96 89 7/11 
Cellai (2005) 831 94 87 70/121 
Yamazaki (2006) 180 98 94 23/25 
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Studies showing local control and larynx preservation for T2 ca of glottis with 
Radiation therapy and Surgical salvage 
Reference 
 
 
Patients 
n 
 
 
Local control 
 
 
Larynx 
Preservation 
 
 
Surgical Salvage 
n/n 
 
Mendenhall et al 
(2001) 
146 
 
96 
 
82 
 
40/49 
 
Wang et al (1990) 
 
173 
 
86 
 
71 
 
28/43 
 
Le et al (1997) 83 92 72 20/27 
Howell-Burke et al 
(1990)  
114 94 74 25/34 
Amornmarn et al 
(1985) 
34 94 88 2/4 
n/n = number of patients salvaged /number of patients who underwent salvage treatment 
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Appendix 5:  
: Summary of trials that demonstrated the feasibility of larynx preservation over 
surgery for locally advanced cancer of the larynx.  
 
 
 
 
 
 
 
Trial 
 
Patients  
n 
 
Stage 
 
Study Arms 
 
Larynx 
Preservation 
VA Trial (1991)  
 (Veterans Affairs) 
332 III/IV 1) Surgery + RT 
Vs 
2) Induction 
chemo + RT 
if CR/PR 
nil 
64% 
 
 
 
EORTC (24891) 
Lefebvre et al 1996 
202  1) Surgery + RT 
Vs 
2) Induction 
chemo + RT 
if CR/PR 
nil 
42% at 3yrs 
35% at 5 yrs 
 
 
RTOG 91-11 
Forastier et al 2003 
547 III/IV 1) RT alone 
Vs 
2) Induction 
chemo + RT 
if CR/PR 
Vs 
3) Cocurrent 
Chemo-RT  
66% 
 
71% 
 
84% 
RT= Radiation Therapy 
CR/PR= Complete Response/ Partial Response 
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Trial 
 
 
Patients 
n 
 
Stage 
 
 
Study Arms 
 
 
Larynx  
Preservation 
 
Overall 
Survival 
 
GORTEC 
Pointreau 
et al. 
2000-01 
 
220  1) 3cycles Induction 
chemo (TPF) 
Vs 
2) 3cycles PF  
> if CR/PR pts had 
RT 
70% at 3yrs 
 
58% at 3yrs 
80% 
 
59% 
 
TAX 324 
Posner et 
al (2007) 
 
501 
 
III/IV 
 
1) 3cycles Induction 
chemo (TPF) 
Vs 
2) 3cycles PF 
> if CR/PR pts had 
CRT  with 
carboplat 
 
 
 
62% at 
3yrs 
 
48% at 
3yrs 
EORTC 
(24954) 
Lefebvre 
et al 2009 
450 T3/T4 
Disease 
1) 2cycles Induction 
chemo (PF) if 
CR/PR pt had CRT 
with PF 
Vs 
2) 4cycles chemo(PF) 
alternating with RT 
wks 1,4,7,10. 
20GY/10# to 60Gy 
No difference  
TPF= Doxetaxel, cisplatin, 5FU 
CR/PR= Complete Response /Partial Response 
CRT= Chemo-Radiation Therapy 
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Appendix 6 
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Appendix 7 
 
Data Sheet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment group = (1) Radical radiotherapy only 
         (2) Radical chemotherapy plus radiotherapy  
         (3) Disease progression (palliative)  
         (4) Advanced disease at presentation (palliative)  
Age  
Gender  
Stage  
Date of 1st visit  
Date treatment started  
Waiting time  
 Treatment group  
Treatment break  
Duration of break  
Treatment completed (Yes/No) and 
date 
 
Radiation dose  
Chemo cycles  
Date at last follow-up   
Improvement of symptoms  
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